$KITE Kite Pharma, Inc. Insider Trading Week 11/2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Kite Pharma, Inc. in week 11/2016.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 7,292 | 50,242 | 86,708 | |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 1,708 | 11,768 | 14,292 | |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 47.82 | 259 | 12,385 | 14,867 | 15.1 K to 14.9 K (-1.71 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 46.49 | 461 | 21,432 | 15,126 | 15.6 K to 15.1 K (-2.96 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 45.32 | 1,538 | 69,702 | 15,587 | 17.1 K to 15.6 K (-8.98 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 44.56 | 6,742 | 300,424 | 17,125 | 23.9 K to 17.1 K (-28.25 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 9,000 | 62,010 | 23,867 | 14.9 K to 23.9 K (+60.54 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 1,006 | 17,102 | 30,575 | |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 7,500 | 5,250 | 56,250 | |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 47.78 | 255 | 12,184 | 10,655 | 10.9 K to 10.7 K (-2.34 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 46.34 | 436 | 20,204 | 10,910 | 11.3 K to 10.9 K (-3.84 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 45.09 | 7,815 | 352,378 | 11,346 | 19.2 K to 11.3 K (-40.79 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 1,006 | 17,102 | 19,161 | 18.2 K to 19.2 K (+5.54 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 7,500 | 5,250 | 18,155 | 10.7 K to 18.2 K (+70.39 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 8,500 | 11,475 | 95,830 | |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 48.07 | 189 | 9,085 | 10,211 | 10.4 K to 10.2 K (-1.82 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 46.55 | 499 | 23,228 | 10,400 | 10.9 K to 10.4 K (-4.58 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 45.12 | 7,812 | 352,477 | 10,899 | 18.7 K to 10.9 K (-41.75 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 8,500 | 11,475 | 18,711 | 10.2 K to 18.7 K (+83.24 %) |
| Mar 16 2016 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Option Exercise | A | 44.91 | 75,000 | 3,368,250 | 75,000 | |
| Mar 16 2016 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Option Exercise | A | 44.91 | 155,000 | 6,961,050 | 155,000 | |
| Mar 16 2016 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |